Navigation Links
Treating sleep disorders in people with traumatic brain injury may not eliminate symptoms
Date:4/14/2009

Westchester, Ill. A study in the April 15 issue of the Journal of Clinical Sleep Medicine is the first to assess the effectiveness of treating sleep disorders in adults with a traumatic brain injury (TBI). Results indicate that treatment may result in the objective resolution of the sleep disorder without improvements in daytime sleepiness or neuropsychological function.

Results show that in brain-injured subjects with obstructive sleep apnea (OSA), three months of treatment with continuous positive airway pressure (CPAP) therapy dramatically reduced the severity of OSA from 31.4 to 3.8 apneas and hypopneas per hour of sleep; however, there was no demonstrable improvement in measures of daytime sleepiness. Participants experienced no significant changes in measures of mood, quality of life and cognitive performance after treatment for a sleep disorder.

According to principal investigator Richard J. Castriotta, M.D., director of the division of Pulmonary, Critical Care and Sleep Medicine at the University of Texas Health Science Center in Houston, researchers were not surprised by the fact that patients with sleep disorders had more severe injuries; however the lack of improvement in excessive sleepiness and neuropsychological testing after treatment was unexpected.

"The TBI patients with sleep apnea and no improvement in sleepiness may have had a combination of pre-existing sleep apnea and posttraumatic hypersomnia, causing sleepiness after the injury," said Castriotta. "These patients may need stimulant therapy in addition to CPAP in order to improve symptoms."

The study involved 57 adults with an average age of 39 years who had suffered a traumatic brain injury at least three months earlier (average 68 months). Seventy-seven percent of the injuries (44) were incurred as a result of a motor-vehicle accident; other causes were assault, a fall or a falling object. Sixty-one percent of the subjects (35) were free of a sleep disorder, while 23 percent (13) had OSA, 7 percent (4) had periodic limb movements in sleep (PLMS), 5 percent (3) had narcolepsy without cataplexy and 3 percent (2) had post-traumatic hypersomnia.

Participants underwent objective evaluation by overnight polysomnography to detect the presence of sleep disorders, and both objective and subjective tests were used to measure daytime sleepliness, mood, quality of life and cognitive performance. Subjects who were diagnosed with OSA received individualized treatment with CPAP therapy while those suffering from narcolepsy, post-traumatic hypersomnia and PLMS received predetermined dosages of medications that were not adjusted after assessment.

According to the authors, research has shown that some OSA patients have residual hypersomnia despite adequate CPAP therapy, which may explain the lack of improvement in measures of daytime sleepiness. Castriotta stated that the study illustrates how difficult it can be to measure the burden of sleep disorders in people with traumatic brain injuries.


'/>"/>

Contact: Kelly Wagner
kwagner@aasmnet.org
708-492-0930
American Academy of Sleep Medicine
Source:Eurekalert

Related medicine news :

1. Study reports success in treating a rare retinal disorder
2. Treating HIV earlier to decrease the risk of death
3. Cellular target may prove useful in treating deadly brain tumors
4. Treating Complicated Grief -- New NIMH Study Seeks 200 Older Adults Suffering from Unrelenting Symptoms of Complicated Grief for Participation in Non-Drug Clinical Trial
5. New Guidelines for Treating Heart Failure
6. Focus on treating malnutrition in cancer patients, researchers say
7. Less is more when it comes to treating high blood pressure
8. New Mexico Doctors Now Treating Brain and Prostate Cancer With RapidArc Radiotherapy Technology
9. Is telmisartan effective in treating non-alcoholic steatohepatitis?
10. Vitamin A signals offer clues to treating autoimmunity
11. Treating drug-addicted doctors is good medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... The Boulevard is honored to host Shriners and Masons Children’s ... located in the Main West Entrance of The Boulevard (in front of JCPenney). ... necessary and each child with a parent or guardian will be photographed for free ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... News Advisory/Interview ... Choice has helped score a major victory in Europe for public health and the ... , Based on rigorous scientific research and the overwhelming support of European citizens, ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: ... A Legacy” is the creation of published author, Desiree M Webb, a registered nurse, ... She has been happily married to her husband, Paul, for over twenty-nine years. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden ... innovative patient - centric payment system, to expand its focus on patient care ... patient financial experience. , “At Ogden Clinic, we are working to become ...
(Date:3/23/2017)... ... ... Trainer”: an electrifying and suspenseful gunslinger novel with a twist. “The Trainer” is ... an enthusiasm for action and adventure stories. , Published by Christian Faith ... at the thirty-three notches that lined the edges of the wooden grip plates of ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 ... Enterprises Limited, anuncia el nombramiento de Stuart ... una plataforma de servicios integrados completa para su ... un cargo clave en el crecimiento y ejecución ... será responsable de impulsar todas las actividades de ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... March 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" ... specialty pharmaceutical company, is pleased to announce that ... approval from the U.S. Food and Drug Administration ... ("ANDA") for tetrabenazine tablets in the 12.5 mg ... is a generic equivalent of the branded product ...
Breaking Medicine Technology: